Bristol-Myers Squibb and bluebird bio have reported positive data from the ongoing Phase I study (CRB-402) of bb21217 for relapsed/refractory multiple myeloma (R/RMM) in patients who did not respond to prior treatments.
bb21217 is an investigational BCMA-targeted chimeric antigen receptor (CAR) T cell therapy being evaluated to treat patients with R/RMM.
Go deeper with GlobalData
The therapy uses the idecabtagene vicleucel (ide-cel; bb2121) CAR molecule and is cultured with the PI3 kinase inhibitor (bb007) to enrich for T cells displaying a memory-like phenotype to increase the in vivo persistence of CAR T cells.
The two-part, open-label, multi-site Phase I CRB-402 study has been designed to assess the primary endpoint of safety and other pre-defined endpoints, including efficacy and pharmacokinetics measurements.
bluebird bio chief medical officer David Davidson said: “Early data from the CRB-402 study in heavily pre-treated patients (median of six prior lines) with relapsed/refractory multiple myeloma demonstrate the potential for durable responses following bb21217 CAR T cell treatment, with a median duration of response of 11.1 months at the 150 x 106 CAR+ T cell dose level.
“Consistent with the hypothesis underlying the bb21217 programme that memory-like phenotype T cells may survive longer in vivo, we have observed durable CAR T cell persistence in evaluable patients (n=2/2) with ongoing response at up to 18 months following treatment.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe data includes results for 38 treated patients as of the 4 September cutoff date.
As part of the study, 24 patients were given bb21217 in the dose-escalation cohort at three dose levels and another 14 received the therapy in the dose-expansion cohort at two dose levels.
The companies are continuing to recruit additional patients in the study and are performing ongoing assessments of the functional persistence of bb21217.
A total of 74 patients are expected to be enrolled for CRB-402, which is currently in the dose-expansion phase.
The trial will further recruit patients and explore bb21217 at the 450 x 106 CAR+ T cells dose cohort, as well as assess functional persistence of bb21217 and durability of response.
